Expert opinion on pharmacotherapy · 2026
Pharmacological solutions for vitiligo: emerging role of Janus kinase inhibitors.
СтатьяОбзорНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Kocic Hristina, Wollina Uwe, Godic Aleksandar, Karanikolic Vesna, Stojkovic-Filipovic Jelena, Golubovic Masa, Valle Yan, Lotti Torello
Аннотация
INTRODUCTION: Vitiligo is a chronic autoimmune condition characterized by progressive loss of melanocytes and the development of depigmented skin lesions. Increasing evidence highlights the pivotal role of dysregulated JAK-STAT signaling in disease pathogenesis.
AREAS COVERED: A literature search was performed using PubMed/MEDLINE, to identify relevant studies published up to January 2026, about the contribution of JAK-STAT-dependent pathways to vitiligo progression, IFN-γ-induced chemokine production (CXCL9 and CXCL10), recruitment of cytotoxic CD8+ T lymphocytes, and the involvement of tissue-resident memory (T < sub > RM</sub>) T cells in maintaining localized immune responses. The effects of JAK inhibition across multiple cell populations, including melanocytes, keratinocytes, and immune cells were examined. Current clinical data regarding both topical and systemic JAK inhibitors in the context of targeted repigmentation strategies.
EXPERT OPINION: Unlike conventional systemic immunosuppressive therapies, JAK inhibitors enable targeted modulation of specific inflammatory pathways central to vitiligo pathophysiology. Future therapeutic success will likely depend on appropriate patient selection, optimal timing of intervention, and rational combination approaches aimed at sustaining repigmentation and reducing relapse risk. Collectively, these developments support the emerging role of JAK-directed therapy as a significant advancement in the management of vitiligo.
AREAS COVERED: A literature search was performed using PubMed/MEDLINE, to identify relevant studies published up to January 2026, about the contribution of JAK-STAT-dependent pathways to vitiligo progression, IFN-γ-induced chemokine production (CXCL9 and CXCL10), recruitment of cytotoxic CD8+ T lymphocytes, and the involvement of tissue-resident memory (T < sub > RM</sub>) T cells in maintaining localized immune responses. The effects of JAK inhibition across multiple cell populations, including melanocytes, keratinocytes, and immune cells were examined. Current clinical data regarding both topical and systemic JAK inhibitors in the context of targeted repigmentation strategies.
EXPERT OPINION: Unlike conventional systemic immunosuppressive therapies, JAK inhibitors enable targeted modulation of specific inflammatory pathways central to vitiligo pathophysiology. Future therapeutic success will likely depend on appropriate patient selection, optimal timing of intervention, and rational combination approaches aimed at sustaining repigmentation and reducing relapse risk. Collectively, these developments support the emerging role of JAK-directed therapy as a significant advancement in the management of vitiligo.